Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 4/2017

01-12-2017 | Position Statement

Diabetes and driving

Authors: Sujoy Ghosh, Sarita Bajaj, Kaushik Pandit, Sanjay Agarwal, SR Aravind, Rajeev Chawla, Sunil Gupta, J Jayaprakashsai, Sanjay Kalra, Ch Vasanth Kumar, Anuj Maheshwari, BM Makkar, CR Anand Moses, Jayanta Panda, Vijay Panikar, PV Rao, Banshi Saboo, Rakesh Sahay, KR Narasimha Setty, Vijay Viswanathan

Published in: International Journal of Diabetes in Developing Countries | Issue 4/2017

Login to get access

Abstract

More than 69 million Indians are suffering from diabetes, of which a substantial proportion of the population are currently holding or will seek in the future the license to drive. Driving essentially requires multitasking with visuospatial skills at the same time and thus the management of diabetes in individuals which should demonstrate a proper detection and treatment of diabetes-related hypoglycemia will predict the capacity of driving any motor vehicle. Repeated hypoglycemia-related neuroglycopenia causes increased risk of neurocognitive dysfunction leading to visuospatial skills deficiency. Eight percent of dementia may be attributed to diabetes. Potential causes of driving impairment associated with diabetes are acute hypoglycemia, and its unawareness, retinopathy, neuropathy related to foot that affects ability to use pedals, IHD, cerebrovascular disease, somnolence and sleep disorder associated with obesity, use of pain relieving medications and antidepressant, and cognitive dysfunction and thus should be reviewed properly before issuing a driving license. Medical evaluation and documentation of acute and chronic complications of drivers by a registered medical practitioner at pre-determined intervals may be considered as a legal necessity to identify at-risk drivers. Secretagogues have a higher incidence of hypoglycemia compared to someone who is on metformin alone. On the other hand, hypoglycemia is more frequent in an insulin-treated patient of both type 1 and type 2 diabetes. In many countries as well as in European Union (EU), it is necessary to review medical fitness in every 3 years by the authority; a person should not have any severe hypoglycemic event in preceding 12 months and a driver must have awareness of hypoglycemia and its management. According to Canadian diabetes association consensus statement, review should be done every 2 years; a person should not have any severe hypoglycemic event in preceding 6 months, and according to ADA position statement evaluation should be done every 2–5 years. Medical fitness certificate should be reviewed at frequent intervals; the authorities should enforce strict regulation on suspension and revocation of driving license. Information to the authorities should be promptly done by doctors or patients. Decision should be based on medical evaluation, but hypoglycemia that occurs due to medication change and during sleep does not warrant for disqualification as it may be corrected with proper dietary changes and dose adjustments. Any driver with suspended license should be re-assessed in the next 6 months for their medical fitness and hypoglycemic profile and if found suitable, the license can be revoked. Physicians should participate and should assess patient’s physical and mental status, medical condition and treatment, list of medications which may impair driving performance, and any disease-related complication that lead to impaired driving or dangerous driving. Patient education is the most important factor to prevent any motor accident related to their medical condition and should be trained to prevent acute and chronic complications of diabetes.
Literature
1.
go back to reference Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al Executive summary. In: IDF Diabetes Atlas. 7th ed. 2015. IDF Diabetes Atlas. 8th ed. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al Executive summary. In: IDF Diabetes Atlas. 7th ed. 2015. IDF Diabetes Atlas. 8th ed.
2.
go back to reference Lorber D, Anderson J, Anderson J, Arent S, Cox DJ, Frier BM, et al. Diabetes and driving. Diabetes Care. 2012;35(1):S81–6.PubMed Lorber D, Anderson J, Anderson J, Arent S, Cox DJ, Frier BM, et al. Diabetes and driving. Diabetes Care. 2012;35(1):S81–6.PubMed
4.
go back to reference Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al. Can J Diabetes. 2013;37:S61–8.CrossRefPubMed Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al. Can J Diabetes. 2013;37:S61–8.CrossRefPubMed
5.
go back to reference American Diabetes Association. Glycemic targets. In: Standards of Medical Care in Diabetes 2017. Diabetes Care. 2017;40(1): S48–S56). American Diabetes Association. Glycemic targets. In: Standards of Medical Care in Diabetes 2017. Diabetes Care. 2017;40(1): S48–S56).
6.
go back to reference Bolo NR, Musen G, Jacobson AM, Weinger K, McCartney RL, Flores V, et al. Brain activation during working memory is altered in patients with type 1 diabetes during hypoglycemia. Diabetes. 2011;60:3256–64.CrossRefPubMedPubMedCentral Bolo NR, Musen G, Jacobson AM, Weinger K, McCartney RL, Flores V, et al. Brain activation during working memory is altered in patients with type 1 diabetes during hypoglycemia. Diabetes. 2011;60:3256–64.CrossRefPubMedPubMedCentral
7.
go back to reference Duning T, Heuvel I, Dickmann A, Volkert T, Wempe C, Reinholz J, et al. Hypoglycemia aggravates critical illness–induced neurocognitive dysfunction. Diabetes Care. 2010;33:639–44.CrossRefPubMed Duning T, Heuvel I, Dickmann A, Volkert T, Wempe C, Reinholz J, et al. Hypoglycemia aggravates critical illness–induced neurocognitive dysfunction. Diabetes Care. 2010;33:639–44.CrossRefPubMed
10.
go back to reference Heller SR, Campbell MJ, Amiel SA, Frier BM, Macleod K, Kerr D, et al. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.CrossRef Heller SR, Campbell MJ, Amiel SA, Frier BM, Macleod K, Kerr D, et al. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.CrossRef
12.
go back to reference American Diabetes Association. Diabetes and driving. Diabetes Care 2014; 37 (Suppl 1): S97- S103. American Diabetes Association. Diabetes and driving. Diabetes Care 2014; 37 (Suppl 1): S97- S103.
14.
go back to reference Signorovitch JE, Macaulay D, Diener M, Yan Y, EQ W, Gruenberger JB, et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes. Obes Metab. 2013;15:335–41.CrossRef Signorovitch JE, Macaulay D, Diener M, Yan Y, EQ W, Gruenberger JB, et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes. Obes Metab. 2013;15:335–41.CrossRef
15.
go back to reference Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other anti-diabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care. 2008;31:2086–91.CrossRefPubMedPubMedCentral Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other anti-diabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care. 2008;31:2086–91.CrossRefPubMedPubMedCentral
16.
go back to reference Inkster B, Frier BM. Diabetes and driving. Diabetes. Obes Metab. 2013:1–9. Inkster B, Frier BM. Diabetes and driving. Diabetes. Obes Metab. 2013:1–9.
17.
go back to reference Houlden RL, Berard L, Cheng A, Kenshole AB, Silverberg J, Woo VC, et al. Diabetes and driving: 2015 Canadian Diabetes Association updated recommendations for private and commercial drivers. Can J Diabetes. 2015;39:347–53.CrossRefPubMed Houlden RL, Berard L, Cheng A, Kenshole AB, Silverberg J, Woo VC, et al. Diabetes and driving: 2015 Canadian Diabetes Association updated recommendations for private and commercial drivers. Can J Diabetes. 2015;39:347–53.CrossRefPubMed
18.
go back to reference Lorber D, Anderson J, Anderson J, Arent S, Cox DJ, Frier BM, et al. Diabetes and driving. Diabetes Care. 2012;35(1):S81–6.PubMed Lorber D, Anderson J, Anderson J, Arent S, Cox DJ, Frier BM, et al. Diabetes and driving. Diabetes Care. 2012;35(1):S81–6.PubMed
Metadata
Title
Diabetes and driving
Authors
Sujoy Ghosh
Sarita Bajaj
Kaushik Pandit
Sanjay Agarwal
SR Aravind
Rajeev Chawla
Sunil Gupta
J Jayaprakashsai
Sanjay Kalra
Ch Vasanth Kumar
Anuj Maheshwari
BM Makkar
CR Anand Moses
Jayanta Panda
Vijay Panikar
PV Rao
Banshi Saboo
Rakesh Sahay
KR Narasimha Setty
Vijay Viswanathan
Publication date
01-12-2017
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 4/2017
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-017-0586-x

Other articles of this Issue 4/2017

International Journal of Diabetes in Developing Countries 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine